278 related articles for article (PubMed ID: 28560593)
21. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
Vaira M; Robella M; Mellano A; Sottile A; De Simone M
Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
[TBL] [Abstract][Full Text] [Related]
22. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
[TBL] [Abstract][Full Text] [Related]
23. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
24. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
[TBL] [Abstract][Full Text] [Related]
25. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
27. Does Intraoperative Systematic Bacterial Sampling During Complete Cytoreductive Surgery (CRS) with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) Influence Postoperative Treatment? A New Predictive Factor for Postoperative Abdominal Infectious Complications.
Dazza M; Schwarz L; Coget J; Frebourg N; Wood G; Huet E; Bridoux V; Veber B; Tuech JJ
World J Surg; 2016 Dec; 40(12):3035-3043. PubMed ID: 27412631
[TBL] [Abstract][Full Text] [Related]
28. The Comprehensive Complication Index: a New Measure of the Burden of Complications After Hyperthermic Intraperitoneal Chemotherapy.
Dumitra S; O'Leary M; Raoof M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Lee B
Ann Surg Oncol; 2018 Mar; 25(3):688-693. PubMed ID: 29260417
[TBL] [Abstract][Full Text] [Related]
29. Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
Kelly KJ; Cajas L; Baumgartner JM; Lowy AM
Ann Surg Oncol; 2018 Jan; 25(1):91-97. PubMed ID: 29090402
[TBL] [Abstract][Full Text] [Related]
30. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
[TBL] [Abstract][Full Text] [Related]
31. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
32. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
33. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures.
Foster JM; Sleightholm R; Patel A; Shostrom V; Hall B; Neilsen B; Bartlett D; Smith L
JAMA Netw Open; 2019 Jan; 2(1):e186847. PubMed ID: 30646202
[TBL] [Abstract][Full Text] [Related]
34. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
Lee L; Alie-Cusson F; Dubé P; Sideris L
J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
[TBL] [Abstract][Full Text] [Related]
35. Restrictive Intraoperative Fluid Therapy is Associated with Decreased Morbidity and Length of Stay Following Hyperthermic Intraperitoneal Chemoperfusion.
Hendrix RJ; Damle A; Williams C; Harris A; Spanakis S; Lambert DH; Lambert LA
Ann Surg Oncol; 2019 Feb; 26(2):490-496. PubMed ID: 30515670
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis in the Elderly: A Case-Controlled, Multicenter Study.
Alyami M; Lundberg P; Kepenekian V; Goéré D; Bereder JM; Msika S; Lorimier G; Quenet F; Ferron G; Thibaudeau E; Abboud K; Lo Dico R; Delroeux D; Brigand C; Arvieux C; Marchal F; Tuech JJ; Guilloit JM; Guyon F; Peyrat P; Pezet D; Ortega-Deballon P; Zinzindohoue F; de Chaisemartin C; Kianmanesh R; Glehen O; Passot G;
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):737-745. PubMed ID: 27600619
[TBL] [Abstract][Full Text] [Related]
37. Cytoreduction and hyperthermic intraperitoneal chemotherapy: The learning curve reassessed.
Kuijpers AM; Hauptmann M; Aalbers AG; Nienhuijs SW; de Hingh IH; Wiezer MJ; van Ramshorst B; van Ginkel RJ; Havenga K; Verwaal VJ
Eur J Surg Oncol; 2016 Feb; 42(2):244-50. PubMed ID: 26375923
[TBL] [Abstract][Full Text] [Related]
38. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Hakeam HA; Arab A; Azzam A; Alyahya Z; Eldali AM; Amin T
Cancer Chemother Pharmacol; 2018 Apr; 81(4):697-704. PubMed ID: 29429054
[TBL] [Abstract][Full Text] [Related]
39. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
[TBL] [Abstract][Full Text] [Related]
40. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
